The expression levels of these three biomarkers (MAFF, ADCYAP1, and ZFP36L1) were further examined in the validation cohort GSE5281 to generate more accurate and reliable results, which were reported to be significantly dysregulated in AD compared with those in the control group. Here, MAFF is linked to Alzheimer disease.